tislelizumab subcutaneous (BGB-A317 SC)
/ BeOne Medicines
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
September 10, 2025
BGB-A317-316: A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
(clinicaltrials.gov)
- P3 | N=351 | Recruiting | Sponsor: BeiGene | Not yet recruiting ➔ Recruiting
Enrollment open • Esophageal Cancer • Gastric Adenocarcinoma • Gastric Cancer • Gastroesophageal Cancer • Gastroesophageal Junction Adenocarcinoma • Oncology • Solid Tumor
June 30, 2025
A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
(clinicaltrials.gov)
- P3 | N=351 | Not yet recruiting | Sponsor: BeiGene
New P3 trial • Esophageal Cancer • Gastric Adenocarcinoma • Gastric Cancer • Gastroesophageal Cancer • Gastroesophageal Junction Adenocarcinoma • Oncology • Solid Tumor
July 14, 2024
A New Treatment Option for Advanced Gastric Cancer?
(NEJM Journal Watch)
- "The addition of the anti–PD-1 agent tislelizumab to first-line chemotherapy improved survival in patients with advanced gastric cancer and PDL-1 scores ≥5%. Adding immune checkpoint inhibitors to first-line chemotherapy for patients with metastatic gastric cancer improves response, progression-free survival (PFS) and overall survival (OS). The benefit is limited to patients testing positive for a combined score for PDL-1."
Clinical
1 to 3
Of
3
Go to page
1